6 August 2015
A single-dose vaccine against ebola has been found to be successful in initial trials, it has been confirmed.
According to researchers at the US National Institute of Allergies and Infectious Diseases, the vaccine offered 100 per cent protection in laboratory tests if administered seven days before exposure, and is partially effective if given just three days before encountering the virus.
It is based on a genetically engineered version of the vesicular stomatitis virus (VSV), which produces symptoms similar to foot and mouth disease in cows, and can also be transmitted to humans. It has previously been used to create vaccines for a number of other viruses.
The researchers believe that the virus-based treatment works in two ways. Initially, it seems to prompt a strong virus-fighting host response, followed by the production of antibodies a week after the vaccination takes place.
The vaccine is now undergoing further clinical trials in humans to see whether it is a safe and effective protection against the deadly virus.
Posted by Jeanette Royston
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.